How some novel combos may be ones to watch out for
Where we look at half a dozen emerging agents and put them through their paces
Dark storm cloud warning from a small cap biotech
How the landscape in prostate cancer could change in the medium to long term
The battle over AR antagonists and degraders rages on as new clinical data emerge
Surprises galore in the unveiling of the PARP data in 1L mCRPC!
Trick or treat? A look at the sotorasib data in PDAC.
An important phase 3 readout to mull over - what's not to like?
Will the eganelisib data be positive in TNBC from the MARIO-3 trial?
Highlights from ASCO GU 2020 with some interesting targets and emerging molecules to consider
What's hot in renal cancers? We take a look at what to expect at ASCO GU19 and offer insights on the emerging data
What can we learn from the key trials being presented at ASCO GU19 in San Francisco?
A review of key abstracts in prostate cancer expected at ASCO GU19 in San Francisco
A look at the changing face of the RCC landscape, including current and near term trial readouts
As inconsistent data abounds, is it time to move on from PD-L1 as a biomarker of response to checkpoint blockade?
A look at some new targeted and IO combinations in development for advanced prostate cancer
Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?
Highlights and Lowlights from ASCO GU 2018 - what to watch out for.
Interview with Dr Daniel George on Phase 3 PROSPER trial results
A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.
A novel non-invasive liquid biopsy may offer a potential novel biomarker that will help in sequencing prostate cancer drugs.
How do we overcome resistance to Zytiga? There are some encouraging developments in this area to report.
Two biotech companies are in a race to market for a novel target in advanced prostate cancer.
Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...
The ongoing story of the AR-V7 splice variant as a potential biomarker of response in mCRPC
The Phase 2 TERRAIN trial met its primary endpoint (PFS) with enzalutamide beating out bicalutamide in castrate resistant prostate cancer. What next?
What's hot at ASCU GU 2015? Focus on prostate and bladder cancers with checkpoint inhibitors and sequencing therapies
The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?
ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.
Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?
Cross resistance between enzalutamide and abiraterone means that new prostate cancer drugs and targets are needed.
At ASCO GU 2014 Tokai Pharmaceuticals report data for the ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer. Is this drug likely to make it to market?
Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial
At ASCO GU this week, the clinical data will be presented for the Medivation/Astellas PREVAIL phase III clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer prior to chemotherapy. The results of this trial not only have important commercial implications for Medivation/Astellas but for competitors in the prostate cancer market.
The share price of Exelixis ($EXEL) is starting a run-up (after months in the doldrums) in advance of anticipated results from the COMET-1 phase 3 trial in metastatic castrate resistant prostate cancer (mCRPC) for cabozantinib (Cometriq, formerly XL184). Cabozantinib has been shown to significantly improve bone scans and decrease pain, but will it show an improvement in OS?
ASCO GU symposium takes place at the San Francisco Marriott Marquis from Jan 20 – February 1, 2014. This preview discusses data to be presented on enzalutamide (Xtandi), abiraterone (Zytiga), ODM-201, ARN-509, ipilimumab (Yervoy).
